Compare Deere & Company (DE) vs Hims and Hers Health Inc (HIMS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Deere & Company vs Hims and Hers Health Inc — how do they compare? Deere & Company trades at $616.53 (market cap $164.47B), while Hims and Hers Health Inc trades at $30.4 (market cap $7.35B). The key difference: Deere & Company is far larger — about 22.4× Hims and Hers Health Inc's market cap, and Deere & Company pays a 1.06% dividend while Hims and Hers Health Inc pays none. Which is the better fit depends on your goals.
| DE | HIMS | |
|---|---|---|
Market Cap | $164.47B | $7.35B |
Sector | Industrials | Health |
52-Week High | $662.49 | $62.76 |
52-Week Low | $439.11 | $14.52 |
Enterprise Value | $219.29B | $7.73B |
Dividend Yield | 1.06% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Deere & Company (DE) trades at $620.83, up 0.97% for the day, with a bullish technical outlook supported by moving averages and recent earnings beats. Revenue declined to $44.67B in 2025, but net income margins remain healthy at 10.33%. The stock is near its pivot point of $620, with support at $613 and resistance at $628. Analyst consensus is a Moderate Buy with a $676.08 price target, reflecting optimism despite cyclical headwinds in agricultural equipment demand.
The outlook is cautiously positive, driven by consistent earnings outperformance and strong institutional holdings, but investors face risks from revenue volatility and high debt levels. The stock offers value if agricultural recovery materializes, but macroeconomic sensitivity warrants monitoring.
Hims & Hers Health stock trades at $31.59, up 6.51% today, showing strong momentum. The technical outlook is bullish, with the price above key moving averages and support at $30. Fundamentally, revenue growth is robust at 40% year-over-year in Q2 2026 (MarketBeat, 2026-08-10), but profitability remains challenged with a net loss margin of -0.56% in 2026. The company raised its annual revenue forecast to $3.1–3.3 billion (WSJ, 2026-08-10), reflecting confidence in subscriber growth and expansion into weight-loss treatments.
The investment outlook is mixed: strong revenue growth and bullish analyst targets near $35.60 offer upside, but high valuation ratios (P/E of 57.14) and recent earnings misses heighten risk. Key risks include margin pressure from GLP-1 investments and ongoing legal investigations. Wall Street sentiment is cautious, with 65% hold ratings, suggesting patience for profitability improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Deere & Company
Deere is the world's leading manufacturer of agricultural equipment, producing some of the most recognizable machines in the heavy machinery industry. The company is divided into four reportable segments: production and precision agriculture, small agriculture and turf, construction and forestry, and John Deere Capital. Its products are available through an extensive dealer network, which includes over 1,900 dealer locations in North America and approximately 3,700 locations globally. John Deere Capital provides retail financing for machinery to its customers, in addition to wholesale financing for dealers, which increases the likelihood of Deere product sales.
Read more on DE →About Hims and Hers Health Inc
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →
